Abstract
Patients with bipolar disorder (BD) and major depressive disorder (MDD) experience psychological distress associated with daily events that do not meet the threshold for traumatic experiences, referred to as event-related psychological distress (ERPD). Recently, we developed an assessment tool for ERPD, the ERPD-24. This tool considers four factors of ERPD: feelings of revenge, rumination, self-denial, and mental paralysis. We conducted a cross-sectional study between March 2021 and October 2022 to identify the differences and clinical features of ERPD among patients with MDD and BD and healthy subjects who did not experience traumatic events. Specifically, we assessed ERPD using the ERPD-24 and anxiety-related symptoms with the State-Trait Anxiety Inventory, Liebowitz Social Anxiety Scale, and anxious-depressive attack. Regarding the ERPD-24 scores among the groups, as the data did not rigorously follow the test of normality, the Kruskal–Wallis test was used to compare the differences among the groups, followed by the Dunn–Bonferroni adjusted post-hoc test. Non-remitted MDD patients and BD patients, regardless of remission/non-remission, presented more severe ERPD than healthy subjects. This study also demonstrated the relationships between all anxiety-related symptoms, including social phobia and anxious-depressive attack and ERPD, in both BD and MDD patients and in healthy subjects. In conclusion, patients with non-remitted MDD and with BD regardless of remission/non-remission experience severe ERPD related to anxiety-related symptoms.
Similar content being viewed by others
Introduction
It is well known that various life events can cause or trigger the onset, relapse, and recurrence of psychiatric disorders. Traumatic events (e.g., wars, disasters, dangerous accidents, abduction, harsh physical and sexual violence in domestic or intimate contexts) are the most serious. Such events can directly cause trauma-related disorders, such as acute stress disorder and post-traumatic stress disorder (PTSD) and constitute one of the diagnostic criteria for these disorders1. However, everyone experiences numerous stressful events in daily life that do not meet the threshold for traumatic experiences. These stressful events (e.g., interpersonal, health, and work-related problems) frequently trigger the onset and relapse of mood disorders2,3.
In previous studies, we found that non-remitted patients with major depressive disorder (MDD)4 and bipolar disorder (BD)5 experience more serious psychological distress associated with daily life events that do not qualify as traumatic experiences—based on Diagnostic Criterion A for PTSD in the DSM-5 and ICD-111,6—compared to remitted patients. Given that everyone can experience non-traumatic life events, it is necessary to deeply understand the psychological distress associated with life events in patients with MDD and BD. Therefore, to precisely evaluate psychological distress associated with life events under the threshold for traumatic experiences, referred to as event-related psychological distress (ERPD), we developed an assessment tool, the ERPD-247, which consists of four factors: feelings of revenge, rumination, self-denial, and mental paralysis8.
This study is the first to examine psychological distress related to daily life events under the traumatic experience threshold among patients with mood disorders using an assessment tool (ERPD-24) specifically designed for this purpose rather than an alternative trauma-specified assessment measure. The purpose of this study was to clarify the features of ERPD—including feelings of revenge, rumination, self-denial, and mental paralysis—in patients with MDD and BD using the ERPD-24 by comparing them to healthy subjects. Based on our previous studies4,5, we hypothesized that the severity of ERPD in non-remitted patients with MDD and BD would be higher than in remitted patients and healthy people. In addition, recent reports suggest that rumination-related negative thinking, which partly overlaps with the concept of ERPD, could be influenced by not only depression but also anxiety9,10,11 and autism12. Therefore, we also explored the relationships between ERPD and various clinical characteristics, such as anxiety-related symptoms, using appropriate measures.
Methods
Ethics statement
The study protocol was approved by the ethics committees of Chiba University Graduate School of Medicine (ID 4047), the International University of Health and Welfare, Chiba Psychiatric Medical Center, Chiba Hospital, Kokoronokaze Clinic Funabashi, and Sodegaura Satsukidai Hospital. All participants provided written informed consent for participation in this study after the procedure was fully explained to them. All the tests were performed in accordance with the Declaration of Helsinki.
Participants and design
This was a cross-sectional study. Participants were recruited from among patients commuting to or hospitalized at Chiba University Hospital, International University of Health and Welfare Narita Hospital, Sodegaura Satsukidai Hospital, Chiba Psychiatric Medical Center, Chiba Hospital, and Kokoronokaze Clinic Funabashi. This study was conducted between March 2021 and October 2022. All patients voluntarily participated. Participants had to meet the following eligibility criteria: (1) aged 20–69 years and (2) no history of traumatic experiences that met the ICD-116 and DSM-5 criteria for PTSD. Individuals who had no ERPD or ERPD-related life events were excluded by assessing their ERPD using the ERPD-24. We interviewed each in- and outpatient face-to-face in a consultation room at each facility for around 60 min.
To recruit patients, we surveyed available in- and outpatients at the research institutes. Patients were included if they were diagnosed with MDD or BD according to the DSM-5 criteria using the Japanese version of the Mini International Neuropsychiatric Interview (M.I.N.I.)13,14. Patients were excluded if they were diagnosed with PTSD, schizophrenia spectrum and other psychotic disorders, neurocognitive disorders (e.g., dementia, organic mental disorders, intellectual disabilities), or imminent suicidal ideation.
We recruited healthy control subjects with social networking ads. Potential control subjects were excluded if they had a history of or were currently diagnosed with psychiatric disorder based on the M.I.N.I., regularly took psychotropic medication, had first-degree relatives with psychiatric disorders, or were pregnant. We also interviewed each healthy subject face-to-face in a consultation room at each facility for around 40 min.
Assessment of depression, mania, and remission
The severity of depression was assessed using the Quick Inventory of Depressive Symptomatology Self-Report, Japanese version (QIDS-J)15,16. We evaluated the severity of mania using the Young Mania Rating Scale (YMRS)17. Remission state was defined by a QIDS-J score ≤ 5 in patients with MDD and by both a QIDS-J score ≤ 5 and a YMRS score ≤ 7 in patients with BD, similar to euthymia. Depressive state was defined as a QIDS-J score > 5 and a YMRS score ≤ 7 in patients with MDD and BD. The manic/hypomanic state was defined as a YMRS score of > 7. We categorized patients who satisfied the diagnostic criteria for mixed features in the DSM-5 as having a QIDS-J score > 5 and a YMRS score > 7 in patients with BD and MDD.
Assessment of ERPD associated with life events under the threshold for traumatic experiences
ERPD comprises psychological phenomena, such as flashbacks, resentment, and regret, related to events considered mundane, such as interpersonal problems and financial difficulties that fall short of experiences that qualify as traumatic under the diagnostic criteria for PTSD in both the DSM-5 and ICD-11. We used the ERPD-24—a self-administered scale that we developed—to assess the severity of the subjects’ ERPD in the week prior to and including the date of their response to our questionnaire7 (Version 1.0 of the ERPD-24 and its instruction manual are presented in the Supplemental File). As stated in the Introduction, the four factors comprising ERPD in the ERPD-24 include “feelings of revenge” (7 items), “rumination” (7 items), “self-denial” (6 items), and “mental paralysis” (4 items).
In our instructions for the ERPD-24, we advise that trauma survivors should be excluded using the diagnostic criteria for PTSD (DSM-5 and ICD-11). The instrument asks respondents to identify the events that still cause them to experience unpleasant memories and feelings and accordingly provide their answers for each item, to specify when the events occurred, how often they had recalled the events in the past month, and how long they have continued to remember the events. Regarding the scoring method, this scale uses a four-point Likert scale, ranging from 0 (not at all) to 3 (very much so). The scores for each option were added, and the scores for the entire scale and for each subscale were calculated. The higher the score for each scale, the higher the severity of ERPD.
Categorizing life events related to ERPD
We classified the participants’ life events regarding ERPD into ten groups based on a list of threatening experiences18: separation from a close person, family problems that do not involve physical and sexual domestic violence or other forms of abuse, health-related problems, interpersonal problems, changes in living conditions, job-related events, sex-related events, neglect, bullying, and other events.
Assessment of anxiety-related symptoms
To assess the severity of anxiety-related symptoms, including social phobia, we used the State-Trait Anxiety Inventory (STAI)19 and the Japanese version of the Liebowitz Social Anxiety Scale (LSAS)20,21.
Anxious-depressive attack (ADA) is a recently proposed symptom cluster consisting of sudden intense feelings of distressing emotions with no direct psychological cause11. ADA is characterized by intrusive rumination on mainly regretful memories accompanied by a violent emotional storm, resulting in countermeasures, including acting out. Based on the original criteria for ADA11, we also evaluated whether patients had ADA or not.
Assessment of other psychological features
Following the evaluation of the ERPD-24, we assessed the Impact of Event Scale-Revised (IES-R)22,23 for the same events as ERPD in this study. We also assessed autistic traits using the Japanese version of the Autism Spectrum Quotient (AQ)24,25. The presence of autistic traits was defined as an AQ score of ≥ 33. Furthermore, among patients with MDD, we also surveyed whether those with bipolarity met the criteria of either bipolar spectrum disorder26 or bipolar specifiers27.
Assessment of clinical characteristics
We surveyed demographic data, including age, sex, comorbidity, educational background, duration of disease, therapy duration, current employment, marital status, and family history of psychiatric diseases in first-degree relatives. Among patients with BD, we diagnosed those with bipolar I or II disorder using the M.I.N.I.
Primary and secondary outcomes
The primary outcome of this study was to identify the differences in ERPD severity (based on the total and factor ERPD-24 scores) among patients with MDD and BD and healthy subjects. The secondary outcomes were to explore the detailed characteristics of ERPD among these groups and to examine the relationships between ERPD and clinical characteristics, such as anxiety symptoms, among these groups.
Statistical analysis
According to the assessment of the mood states of depression, mania, and remission (euthymia in BD) outlined above, we classified the participants into the six following groups: depressive BD patients, manic/hypomanic BD patients, remitted BD patients, non-remitted (i.e., depressed) MDD patients, remitted MDD patients, and healthy subjects. All analyses were conducted using SPSS version 28 (IBM Corporation, Armonk, NY, USA). For categorical variables, the chi-square test was used. We used Student’s t-test to compare the two groups. We used the Kruskal–Wallis test for the other variables because the data regarding the ERPD in the subgroups did not rigorously follow the test of normality. To compare the differences among the groups, we used the Dunn–Bonferroni adjusted post-hoc test after the Kruskal–Wallis test. Pearson correlation tests were conducted to examine the correlations between the ERPD scores and other psychometric data. The 95% confidence interval (CI) was used to estimate precision, and a p < 0.05 was considered significant.
Results
Participants’ characteristics
Figure 1 shows a flowchart of eligible candidates and subjects who participated in this study. Ultimately, 95 patients with MDD and BD (76 outpatients and 19 inpatients) and 31 healthy volunteers were eligible to participate. Of these patients, 11 declined to participate and four were unable to complete the interview. Finally, 80 patients with MDD (n =38) and BD (n =42) and 31 healthy subjects were included. All participants reported that they had experienced at least one ERPD or ERPD-related event. The participants’ characteristics are shown in Table 1. Table 2 details the psychiatric comorbidities among the patients with BD and MDD.
Classification of life events related to ERPD
Table 3 shows life events related to ERPD for all participants. Of the 23 participants with overlapping ERPD-related events, only one—a patient with BD—reported three ERPD-related events.
Length of occurrence of life events, frequency, and sustained duration of ERPD
Table 3 also shows time-related information for ERPD. Regarding the length of the occurrence of life events related to ERPD, there were no correlations between length and total ERPD-24 scores in patients with MDD and BD and healthy subjects. In terms of each ERPD-composing factor, there was a significant negative correlation between the length and the scores of “self-denial” (r = − 0.35, p < 0.05) in patients with BD and a significant positive correlation between the length and scores of “mental paralysis” (r = 0.44, p < 0.05) in healthy subjects. The scores for the other ERPD factors—“feelings of revenge” and “rumination”—did not correlate with length.
Regarding ERPD occurrence frequency, significant positive correlations were found between frequency and the scores for total ERPD-24 (r = 0.47, p < 0.01), “rumination” (r = 0.63, p < 0.01), “self-denial” (r = 0.47, p < 0.01), and “mental paralysis” (r = 0.40, p < 0.05) in patients with MDD. Among BD patients, there were no positive correlations between frequency and the scores for total ERPD-24 and “self-denial”; meanwhile, frequency demonstrated a significant positive correlation with “rumination” and “mental paralysis” in this group. There were no correlations between frequency and any type of ERPD-24 score in healthy subjects.
In terms of the duration of ERPD, there were no correlations between length and any type of ERPD-24 score in patients with BD or healthy subjects. Conversely, duration was positively correlated with the total ERPD-24 score (r = 0.40, p < 0.05) and the scores for “rumination” (r = 0.38, p < 0.05) and “self-denial” (r = 0.44, p < 0.01) in patients with MDD (there were no correlations between duration and the scores for “feelings of revenge” and “mental paralysis” in this group).
The severity of ERPD among the groups
A test for the normality of the ERPD using the Shapiro–Wilk test did not assume normality. Additionally, the tests for the homogeneity of variances in the ERPD-24 scores were not uniform, except for “self-denial”. Therefore, we used the Kruskal–Wallis test to compare the differences between the groups, followed by the Dunn–Bonferroni adjusted post-hoc test for multiple comparisons. There were significant differences among the six groups in the ERPD-24 total score and the scores for “feelings of revenge”, “rumination”, “self-denial”, and “mental paralysis” (p < 0.01). The post-hoc analysis showed significant differences between the groups (Fig. 2). As Fig. 2 outlines, the total score and the scores for “feelings of revenge,” “rumination,” and “mental paralysis” in non-remitted MDD patients and BD patients across different states (i.e., depressive, manic/hypomanic, and remitted) were significantly higher than those in healthy subjects, although those in remitted MDD patients were not significant. The scores for “self-denial” were significantly higher in non-remitted MDD patients and depressive- and remission-state BD patients than in healthy subjects. Conversely, there were no significant differences in the scores for “self-denial” across remitted MDD and manic/hypomanic BD patients compared to healthy subjects.
Relationship between ERPD and anxiety-related symptoms
Table 4 shows the results for ERPD and anxiety-related psychometrics in patients with MDD and BD. Regarding depression, there were significant positive correlations between the QIDS-J scores and the total ERPD-24 score and the scores for “rumination,” “self-denial,” and “mental paralysis”; the score for “feelings of revenge” was not correlated with the QIDS-J scores in patients with BD (Table 4). Likewise, there were significant positive correlations between the QIDS-J scores and the total score for the ERPD-24 as well as the scores for “self-denial”; the scores for “feelings of revenge”, “rumination”, and “mental paralysis” were not correlated with the QIDS-J scores among healthy subjects (Table 4). Conversely, there were no correlations between the QIDS-J scores and the total score for the ERPD-24 and the scores for “feelings of revenge”, “rumination”, and “self-denial” in patients with MDD, even though only the score for “mental paralysis” was positively correlated with the QIDS-J scores for this group (Table 4).
Regarding anxiety-related symptoms, the scores for both the STAI-state and STAI-trait were significantly positively correlated with the total score for the ERPD-24 and the scores for “rumination” and “mental paralysis” in the BD and MDD groups (Table 4). Among healthy subjects, the positive correlations between the scores for the STAI trait were significantly positively correlated with those for the ERPD-24, although there were no correlations between the scores for the STAI-state and the ERPD-24 (Table 4). The scores for the LSAS were significantly positively correlated with the total score for the ERPD-24 and the score for “rumination” in all three groups (Table 4). In terms of ADA, among the BD and MDD patient groups, all ERPD-24 scores were significantly higher in those with ADA than in those without ADA (Table 5).
Relationship between the other psychometrics and ERPD
Regarding the relationship between the scores for the ERPD-24 and those for the IES-R, Table 4 shows that almost all scores for the ERPD-24 (i.e., the scores for “feelings of revenge,” “rumination,” “self-denial,” and “mental paralysis”) were significantly positively correlated with those for the IES-R (including total, intrusion, avoidance, and hyperarousal) in patients with MDD, BD, and healthy subjects; however, there was no relationship between the scores for “self-denial” and avoidance in BD patients and the scores for “self-denial” and the IES-R total and sub-component scores.
The ERPD-24 total score and the scores for “rumination” and “mental paralysis” in MDD patients with bipolarity were significantly higher than in those without bipolarity.
Of the total patients, 11 patients (five with MDD and six with BD) with autistic traits were included in this study. A BD patient with autism spectrum disorder scored 31 on the AQ-J (notably, this is < 33). There were no significant differences in the total ERPD-24 score and the ERPD-24 scores for the four comprising factors between patients with MDD and BD with and without autistic traits.
Discussion
This study had three main findings. First, non-remitted MDD patients and BD patients regardless of remission/non-remission (i.e., manic/hypomanic and depressive state), presented more severe ERPD associated with life events under the threshold for traumatic experiences (given by diagnostic criteria for PTSD) than healthy subjects. Second, this study presents the details of ERPD, including temporal information. Third, anxiety-related symptoms, including social phobia and ADA, could be associated with ERPD not only in patients with BD and MDD, but also in healthy subjects.
This is the first study to present the details of ERPD in patients with BD, MDD, and healthy subjects. Regarding the relationship between the duration of occurrence of ERPD-related events and severity, length only correlated with ERPD severity under “self-denial” in patients with BD and “mental paralysis” in healthy subjects. According to similar previous studies on mood disorders28 and PTSD29, the length of occurrence of stressful events weakly influences the severity and, relatedly, prognosis of these diseases. Adverse childhood experiences have been found to have a prolonged negative influence on various psychiatric disorders in adults30,31,32,33. Moreover, given that various forms of cognitive dysfunction exist among remitted patients with BD34, even if BD patients experience symptomatic remission, they may be likely to have or ruminate on feelings of self-denial related not only to their past but also to more recent life events. As an ERPD-composing factor, self-denial might lead a patient to be more vulnerable to recurrence or relapse because the DSM-5 criteria for a major depressive episode in BD include “feeling worthless or excessive/inappropriate guilt”; this is similar to thoughts and feelings of self-denial. This study adds to the existing research on this topic by revealing that the severity of ERPD may be slightly linked to the duration of occurrence of an ERPD-related event.
Additionally, regarding the length of occurrence of life events in ERPD, the present study shows a significant positive correlation between the length and scores of “mental paralysis” only in healthy people. According to the ERPD-24 scale (as seen in the Supplemental File), “mental paralysis” as an ERPD-composing factor consists of four experiences: heaviness, fogginess, a loss of concentration, and a loss of will or intention when recalling ERPD-related events. Conversely, there are no correlations between the length of the occurrence of ERPD-related life events and the scores of “mental paralysis” among the BD and MDD patient groups. Accumulating evidence reports that BD and MDD patients, regardless of symptomatic remission/non-remission, suffer from cognitive impairment including concentration35,36. Therefore, cognitive impairment may influence “mental paralysis” comprising initiative and concentration in BD and MDD patients. Our findings suggest that having more past experiences leading to episodic memories may have a stronger impact on ERPD, especially among healthy people with mental paralysis. To further clarify this finding, further studies with larger sample sizes are needed.
Conversely, this study reveals that the frequency of occurrence and duration of ERPD are positively correlated with the severity of ERPD in patients with MDD, although they are not correlated in healthy subjects. According to previous reports, depressed individuals have difficulty suppressing involuntary thoughts37 and autobiographical memories38; these neuropsychological phenomena may overlap with ERPD. To improve understandings of and treatments for MDD, researchers and physicians should carefully focus on ERPD and related psychological features in depressed patients.
No correlations between the frequency and duration of the occurrence of ERPD and the severity of ERPD were found among BD patients; however, “rumination” and “mental paralysis” were partly positively correlated with frequency in this group. Given that various psychological conditions occur in BD patients with depression, mania/hypomania, and euthymia, the components of ERPD may vary among patients with BD. Therefore, the small sample size of the present study may have not be able to clarify the correlations between the frequency and duration of the occurrence and the severity of ERPD. Further studies with a large sample size and observational cohort design are needed to clarify the association between ERPD and mood states in BD.
This study found that, compared to healthy subjects, patients with non-remitted MDD, and BD regardless of remission/non-remission, experience more psychological distress associated with past events in daily life (i.e., they experience ERPD, consisting of feelings of revenge, rumination, self-denial, and mental paralysis), even if these events are necessarily under the traumatic experience threshold set by the diagnostic criteria for PTSD. These findings are mainly consistent with our hypothesis, although the severity of ERPD in remitted BD patients was higher than that in healthy people. Regarding MDD, the present findings are consistent with our previous study’s4 observation that psychological distress is associated with disease-onset events in daily life in non-remitted MDD patients (this study used the IES-R). Additionally, this study contributes to existing knowledge about psychopathology in mood disorders by revealing that MDD patients currently in a depressive state (i.e., non-remission) experience more ERPD characterized by self-denial, rumination, mental paralysis, and feelings of revenge in relation to past life events than healthy subjects. Regarding feelings of revenge, several previous studies report that patients with depression demonstrate trait anger/hostility39,40 and irritability41. Accordingly, our findings imply that depressed patients may have ambivalent feelings, such as feelings of revenge and self-denial, when they recall their past life events and experience ERPD.
Conversely, patients with BD, regardless of whether they were in a remission or non-remission state, experienced severe ERPD in this study. This finding is somewhat surprising: our previous study reported that euthymic BD patients have milder ERPD than depressive and manic/hypomanic (i.e., non-remitted) ones5. This may have occurred because we asked participants about onset-related and onset-unrelated past events at the same time during face-to-face interviews in this earlier study. Ultimately, 70.9% (n = 56) of patients answered that they felt that they had experienced both kinds of events, and 19.6% (n = 11) responded that the events were the same5. The ERPD-24-based method used in the current study may more accurately identify ERPD than the method used in our previous study. However, further studies with larger sample sizes are needed to reveal the association between ERPD and mood states in BD patients.
This study revealed a strong association between anxiety-related symptoms and ERPD in both BD and MDD patients and healthy subjects. Turner et al. reported that intrusive thoughts characterized by worry, including those related to obsessive–compulsive and anxiety disorders, may occur more frequently in people with mood disorders42. In addition, previous studies have suggested a relationship between interpersonal problems and mental problems, including social anxiety, rejection sensitivity, and depression43,44. These findings support those of the present study regarding the relationship between ERPD. Furthermore, among patients with MDD and BD, the total ERPD scores of patients with ADA were higher than those of patients without ADA. According to Kaiya’s proposal of the concept of ADA11, ADA is similar to panic attacks in the brain; notably, both are accompanied by intrusive thoughts and rumination. Interestingly, ADA level has been associated with rejection sensitivity45. These findings suggest that ERPD may be especially associated with social anxiety and rejection sensitivity, and that severe ERPD may occur with ADA in patients with mood disorders and other psychiatric diseases. In addition, this study also found that a relationship exists between ERPD and anxiety. Almost all healthy people experience anxiety or fear in daily life42, although previous studies report that the degree of anxiety is lower in those with anxiety disorders, especially those with generalized anxiety disorder41,46. Therefore, once healthy subjects with a threshold clinical mental illness experience anxiety, they may experience ERPD associated with past events. Further studies are needed to reveal the relationship between ERPD and anxiety-related assessments.
Regarding depression, the severity of depression in patients with MDD was not correlated with the ERPD scores in this study, except regarding mental paralysis; however, positive correlations were found between depression severity in patients with BD and healthy subjects. This finding differs from those of our previous studies that showed the relationships between the severity of depression and that of ERPD in patients with MDD and BD4,5, perhaps because we used different assessment tools to measure depression severity. The QIDS-J includes symptoms of hypersomnia and increased appetite, which are not considered by the Hamilton Depression Rating Scale (HAMD)47. In addition, there is a difference in raters: the QIDS-J is a self-administered scale; the HAMD was assessed by physicians or researchers Nevertheless, since the relationship between the QIDS-J and HAMD is obvious, further studies with a large sample size are needed to confirm this.
The concept of ERPD can provide new insights and perspectives from the clinical presentation to the pathophysiology in patients with MDD and BD. In clinical insights, considering the existence of ERPD rather than focusing on well-known terminological symptoms such as depressed mood, could promote a better understanding of the complex and various psychiatric pathology and behaviours in patients with MDD and BD. For instance, regarding hopelessness and demoralization in suicidal behaviour, as one of the most important psychiatric conditions48, the insights of ERPD might help researchers resolve the pathophysiology with potential new approaches, including considering neuroinflammatory abnormalities such as the kynurenine pathway49,50 in patients with MDD and BD. The presentation of ERPD could contribute to further studies that can challenge the current understanding and the management of mood disorders.
This study had some limitations. First, this study only examined six groups, which meant that it was likely to yield complex results. Second, the study may have involved subject recall bias. Third, the sample size was small. Considering BD and MDD patients were divided into three (BD mania/hypomania, BD depression, and BD remission) and two (MDD depression and remission) subgroups to compare them with healthy subjects, the implementation of a large sample size could further clarify the differences between the severity and contents of ERPD among the groups. Finally, this was a cross-sectional study, and it did not identify or investigate changes in ERPD among the participants. To overcome these problems, a prospective study with a larger sample size for each group is needed.
In conclusion, this study demonstrated that patients with non-remitted MDD, and BD regardless of remission/non-remission, more frequently experience severe ERPD associated with life events under the threshold for traumatic experiences than healthy subjects. Considering that depressive disorders, in which one-third of patients do not reach remission51, have the highest burden on global health of all psychiatric diseases52, and that almost all patients with BD need long-term treatment53, many patients with mood disorders can be thought to be suffering from ERPD. ERPD can provide psychiatrists with new insights into the clinical features of mood disorders; in particular, focusing on ERPD can improve their understanding of psychopathology in patients with MDD and BD. Furthermore, we found that ERPD is associated with anxiety. These findings are useful because they may encourage researchers and physicians to focus on such patients with ERPD, who may otherwise have been overlooked.
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
American Psychiatric Association. Diagnostic & Statistical Manual of Mental Disorders, 5th ed. (2013).
Kendler, K. S. & Gardner, C. O. Dependent stressful life events and prior depressive episodes in the prediction of major depression: The problem of causal inference in psychiatric epidemiology. Arch. Gen. Psychiatry 67, 1120–1127 (2010).
Lex, C., Bäzner, E. & Meyer, T. D. Does stress play a significant role in bipolar disorder? A meta-analysis. J. Affect. Disord. 208, 298–308 (2017).
Kimura, A., Hashimoto, T., Niitsu, T. & Iyo, M. Presence of psychological distress symptoms associated with onset-related life events in patients with treatment-refractory depression. J. Affect. Disord. 175, 303–309 (2015).
Sato, A., Hashimoto, T., Kimura, A., Niitsu, T. & Iyo, M. Psychological distress symptoms associated with life events in patients with bipolar disorder: A cross-sectional study. Front. Psychiatry. 9, (2018).
WHO. International Statistical Classification of Diseases and Related Health Problems, 11th revision. (2022).
Seki, R. et al. ERPD-24. Chiba University. https://www.m.chiba-u.ac.jp/class/psy3/education/erpd24.html (accessed 6 May 2024).
Seki, R. et al. Identification of psychological features and development of an assessment tool for event-related psychological distress after experiencing non-traumatic stressful events. PLoS One 16, e0249126 (2021).
Watkins, E. R. et al. Rumination-focused cognitive-behavioural therapy for residual depression: Phase II randomised controlled trial. Br. J. Psychiatry 199, 317–322 (2011).
Bell, I. H. et al. The effect of psychological treatment on repetitive negative thinking in youth depression and anxiety: A meta-analysis and meta-regression. Psychol. Med. 53, 1–11 (2022).
Kaiya, H. Distinctive clinical features of “Anxious-Depressive Attack”. Anxiety Disord. Res. 9, 2–16 (2017).
Ibrahim, K. et al. Anger rumination is associated with restricted and repetitive behaviors in children with autism spectrum disorder. J. Autism Dev. Disord. 49, 3656–3668 (2019).
Otsubo, T. et al. Reliability and validity of Japanese version of the mini-international neuropsychiatric interview. Psychiatry Clin. Neurosci. 59, 517–526 (2005).
Sheehan, D. et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 59(Suppl 2) (1998).
Rush, A. J. et al. The 16-item Quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573–583 (2003).
Fujisawa, D. et al. Cross-cultural adaptation of the quick inventory of depressive symptomatology-self report (QIDS-SR-J). Jpn. J. Stress Sci. 25, 43–52 (2010).
Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: Reliability, validity and sensitivity. Br. J. Psychiatry 133, 429–435 (1978).
Brugha, T. S. & Cragg, D. The list of threatening experiences: The reliability and validity of a brief life events questionnaire. Acta Psychiatr. Scand. 82, 77–81 (1990).
Spielberger, C., Gorsuch, R., Lushene, R., Vagg, P. R. & Jacobs, G. Manual for the State-Trait Anxiety Inventory (Form Y1–Y2), vol. IV (Consulting Psychologists Press, 1983).
Mizuguchi, K., Simonaka, J. & Nakasato, K. Japanese Version STAI Manual 23–49 (Consult. Psychol. Press. Palo Alto, 1970).
Asakura, S. et al. Reliability and validity of the Japanese version of the Liebowitz social anxiety scale. Seishin Igaku Clin. Psychiatry 44, (2002).
Weiss, D. S. & Marmar, C. R. The impact of event scale-revised. In Assessing Psychological Trauma and PTSD: A Handbook for Practitioners. 399–451 (Guilford Press, 1997).
Asukai, N. et al. Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): Four studies of different traumatic events. J. Nerv. Ment. Dis. 190, 175–182 (2002).
Baron-Cohen, S., Wheelwright, S., Skinner, R., Martin, J. & Clubley, E. The autism-spectrum quotient (AQ): Evidence from Asperger syndrome/ high-functioning autism, males and females, scientists and mathematicians. J. Autism Dev. Disord. 31, 5–17 (2001).
Wakabayashi, A., Tojo, Y., Baron-Cohen, S. & Wheelwright, S. The autism-spectrum quotient (AQ) Japanese version: Evidence from high-functioning clinical group and normal adults. Jpn. J. Psychol. 75, 78–84 (2004).
Ghaemi, S. N., Ko, J. Y. & Goodwin, F. K. ‘Cade’s disease’ and beyond: Misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can. J. Psychiatry. 47, 125–134 (2002).
Angst, J. et al. Toward a re-definition of subthreshold bipolarity: Epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J. Affect. Disord. 73, 133–146 (2003).
Roca, M. et al. Stressful life events severity in patients with first and recurrent depressive episodes. Soc. Psychiatry Psychiatr. Epidemiol. 48, 1963–1969 (2013).
Bryant, R. A., O’Donnell, M. L., Creamer, M., McFarlane, A. C. & Silove, D. A multisite analysis of the fluctuating course of posttraumatic stress disorder. JAMA Psychiatry 70, 839–846 (2013).
Park, Y. M., Shekhtman, T. & Kelsoe, J. R. Effect of the type and number of adverse childhood experiences and the timing of adverse experiences on clinical outcomes in individuals with bipolar disorder. Brain Sci. 10, 254 (2020).
LeMoult, J. et al. Meta-analysis: Exposure to early life stress and risk for depression in childhood and adolescence. J. Am. Acad. Child Adolesc. Psychiatry 59, 842–855 (2020).
Daniel, W. H. & Joan, K. Adverse childhood experiences in children with autism spectrum disorder. Curr. Opin. Psychiatry 31, 128–132 (2018).
Crouch, E., Radcliff, E., Bennett, K. J., Brown, M. J. & Hung, P. Examining the relationship between adverse childhood experiences and ADHD diagnosis and severity. Acad. Pediatr. 21, 1388–1394 (2021).
Solé, B. et al. Cognitive impairment in bipolar disorder: Treatment and prevention strategies. Int. J. Neuropsychopharmacol. 20, 670–680 (2017).
Little, B. et al. Processing speed and sustained attention in bipolar disorder and major depressive disorder: A systematic review and meta-analysis. Bipolar Disord. 26, 109–128 (2024).
Semkovska, M. et al. Cognitive function following a major depressive episode: A systematic review and meta-analysis. Lancet Psychiatry. 6, 851–861 (2019).
Wenzlaff, R. M. & Wegner, D. M. Thought suppression. Annu. Rev. Psychol. 51, 59–91 (2000).
Watson, L. A., Berntsen, D., Kuyken, W. & Watkins, E. R. The characteristics of involuntary and voluntary autobiographical memories in depressed and never depressed individuals. Conscious. Cogn. 21, 1382–1392 (2012).
de Bles, N. J. et al. Trait anger and anger attacks in relation to depressive and anxiety disorders. J. Affect. Disord. 259, 259–265 (2019).
Fisher, L. B. et al. The role of anger/hostility in treatment-resistant depression: A secondary analysis from the ADAPT-A study. J. Nerv. Ment. Dis. 203, 762–768 (2015).
Fava, M. et al. The importance of irritability as a symptom of major depressive disorder: Results from the national comorbidity survey replication. Mol. Psychiatry 2010 158 15, 856–867 (2009).
Dupuy, J. B., Beaudoin, S., Rhéaume, J., Ladouceur, R. & Dugas, M. J. Worry: Daily self-report in clinical and non-clinical populations. Behav. Res. Ther. 39, 1249–1255 (2001).
Normansell, K. M. & Wisco, B. E. Negative interpretation bias as a mechanism of the relationship between rejection sensitivity and depressive symptoms. Cogn. Emot. 31, 950–962 (2017).
Gao, S., Assink, M., Cipriani, A. & Lin, K. Associations between rejection sensitivity and mental health outcomes: A meta-analytic review. Clin. Psychol. Rev. 57, 59–74 (2017).
Kaiya, H. et al. Effects of rejection sensitivity on the development of anxious-depressive attack in patients with social anxiety disorder. Anxiety Disord. Res. 12, 37–44 (2020).
Craske, M. G., Rapee, R. M., Jackel, L. & Barlow, D. H. Qualitative dimensions of worry in DSM-III-R generalized anxiety disorder subjects and nonanxious controls. Behav. Res. Ther. 27, 397–402 (1989).
Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56–62 (1960).
Costanza, D. et al. Demoralization in suicide: A systematic review. J. Psychosom. Res. 157, 110788 (2022).
Serafini, G. et al. Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: A systematic review. CNS Neurol. Disord. Drug Targets. 16, 440–453 (2017).
Savitz, J. The kynurenine pathway: A finger in every pie. Mol. Psychiatry. 25, 131–147 (2020).
Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 163, 1905–1917 (2006).
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 396, 1204–1222 (2020).
Yatham, L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20, 97–170 (2018).
Acknowledgements
We would like to thank Editage (http://www.editage.jp) for the English language editing of our manuscript. We would also like to thank all participants in this study.
Funding
This study was implemented by the financial support of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grants-in-Aid for young scientists (No.20K16616). This foundation had no role in the study’s design, collection, analysis, interpretation of data, writing of the report, and the decision to submit the article for publication.
Author information
Authors and Affiliations
Contributions
Conception and design of the study: H.I., T.H., A.S., R.S., M.O., A.K., and M.T. Acquisition of data: H.I., R.S. Conducting the statistical analysis: H.I., T.H. and M.T. Interpretation of the data: H.I., T.H., A.S., R.S., M.O., A.K., M.T., and M.I. Drafting of the manuscript and figures: H.I., T.H. and M.T. M.N. and M.I. played the role of supervisors in this study. All authors contributed to revising the manuscript and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
T.H. received research fundings from Japan Research Foundation for Clinical Pharmacology, Mitsubishi Foundation, and READYFOR Corporation. M.I. received consultant fees from Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Abbott Japan Co., Ltd. and Janssen Pharmaceutical K.K., and reports honoraria from Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., MSD K.K., Eisai Co. Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., Teijin Ltd., Shionogi & Co., Ltd., Hisamitsu Pharmaceutical Co., Inc. and Asahi Kasei Corporation. M.N. reports honoraria from Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., and Lundbeck Japan K.K. A.S. reports honoraria from Takeda Pharmaceutical Co., Ltd., and Lundbeck Japan K.K. A.K. reports honoraria from Takeda Pharmaceutical Co., Ltd. The other authors declare that they have no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ishii, H., Hashimoto, T., Sato, A. et al. Evaluating psychological distress associated with life events under the traumatic experience threshold in patients with major depressive and bipolar disorder. Sci Rep 14, 16264 (2024). https://doi.org/10.1038/s41598-024-67101-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-67101-x
- Springer Nature Limited